转移性去势抵抗性前列腺癌患者接受芦卡帕利治疗后BRCA回复突变的出现
在TRITON2研究中,100例BRCA突变转移性去势抵抗性前列腺癌患者接受芦卡帕利治疗后进展,血浆游离DNA二代测序显示39%出现体细胞BRCA回复突变,且与治疗持续时间及客观或PSA缓解相关,提示回复突变是获得性耐药机制。
要点
- 100例BRCA突变mCRPC患者基线均无BRCA回复突变,芦卡帕利进展后39%检出体细胞回复突变。
- 有客观缓解者回复突变频率58%、有PSA缓解者69%,均高于无缓解者的39%和29%。
- 多数回复突变(74%)为亚克隆性且等位基因频率低于原始BRCA突变。
核心结论
- BRCA回复突变是BRCA突变mCRPC患者对芦卡帕利获得性耐药的重要机制,并可见亚克隆汇聚促进系统性耐药。
研究设计与样本
- TRITON2研究纳入接受一至两线雄激素受体靶向治疗及一种紫杉烷类治疗后进展的BRCA突变mCRPC男性患者,接受芦卡帕利治疗;对截至2020年5月5日确认进展后治疗结束时采集的100例患者血浆游离DNA进行二代测序检测BRCA回复突变。
主要发现
- 100例BRCA突变患者基线均未观察到BRCA回复突变,进展后二代测序检出体细胞BRCA回复突变39%(39/100)。
- BRCA2与BRCA1的回复突变率相似,与胚系或体细胞状态无关,但在肿瘤DNA分数高的样本中更高。
- 多数回复突变患者(74%,29/39)有两个或以上回复突变,呈亚克隆性且等位基因频率低于原始BRCA突变。
- BRCA回复突变发生率随芦卡帕利治疗持续时间延长而增加。
- 有客观缓解者回复突变频率为58%、有PSA缓解者为69%,分别高于无客观缓解者的39%和无PSA缓解者的29%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are approved in the USA for the treatment of patients with BRCA1 or BRCA2 (BRCA) mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). BRCA reversion mutations are a known mechanism of acquired resistance to PARP inhibitors in multiple cancer types, although their impact and prevalence in mCRPC remain unknown. OBJECTIVE: To examine the prevalence of BRCA reversion mutations in the plasma of patients with BRCA+ mCRPC after progression on rucaparib. DESIGN, SETTING, AND PARTICIPANTS: Men with BRCA+ mCRPC enrolled in Trial of Rucaparib in Prostate Indications 2 (TRITON2) were treated with rucaparib after progressing on one to two lines of androgen receptor-directed and one taxane-based therapy. Cell-free DNA from the plasma of 100 patients, collected at the end of treatment after confirmed progression before May 5, 2020, was queried for BRCA reversion mutations using next-generation sequencing (NGS). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The association of clinical efficacy and postprogression genomics was measured in 100 patients with BRCA+ mCRPC treated with rucaparib. RESULTS AND LIMITATIONS: No baseline BRCA reversion mutations were observed in 100 BRCA+ patients. NGS identified somatic BRCA reversion mutations in 39% (39/100) of patients after progression. Reversion rates were similar for BRCA2 and BRCA1, irrespective of germline or somatic status, but higher in samples with a high tumor DNA fraction. Most patients with reversions (74%, 29/39) had two or more reversion mutations occurring subclonally at lower allele frequencies than the original BRCA mutations. The incidence of BRCA reversion mutations increased with the duration of rucaparib treatment. The frequency of reversion mutations was higher in patients with an objective (58%) or a prostate-specific antigen (69%) response compared with those without either (39% and 29%, respectively). CONCLUSIONS: These findings suggest that BRCA reversion mutations are a significant mechanism of acquired resistance to rucaparib in patients with BRCA+ mCRPC, with evidence of subclonal convergence promoting systemic resistance. PATIENT SUMMARY: Men with BRCA mutated metastatic castration-resistant prostate cancer enrolled in TRITON2 were treated with rucaparib after progressing on one to two lines of androgen receptor-directed and one taxane-based therapy. Cell-free DNA from the plasma of 100 patients, collected after radiographic or prostate-specific antigen progression before May 5, 2020, was analyzed by next-generation sequencing and queried for BRCA reversion mutations.
引用
- Loehr A, Hussain A, Patnaik A, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. 2022. PMID: 36243543. doi:10.1016/j.eururo.2022.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。